AWZ1066S, a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis

Collapse authors list.
Hong, W David, Benayoud, Farid, Nixon, Gemma L, Ford, Louise, Johnston, Kelly L, Clare, Rachel H, Cassidy, Andrew, Cook, Darren AN, Siu, Amy, Shiotani, Motohiro et al (show 24 more authors) , Webborn, Peter JH, Kavanagh, Stefan, Aljayyoussi, Ghaith, Murphy, Emma, Steven, Andrew, Archer, John, Struever, Dominique, Frohberger, Stefan J, Ehrens, Alexandra, Huebner, Marc P, Hoerauf, Achim, Roberts, Adam P, Hubbard, Alasdair TM, Tate, Edward W, Serwa, Remigiusz A, Leung, Suet C, Qie, Li, Berry, Neil G ORCID: 0000-0003-1928-0738, Gusovsky, Fabian, Hemingway, Janet, Turner, Joseph D, Taylor, Mark J, Ward, Stephen A and O'Neill, Paul M ORCID: 0000-0003-4338-0317 (2019) AWZ1066S, a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 116 (4). pp. 1414-1419.

	Text Hong_AWZ1066S_PNAS final accepted version.pdf - Author Accepted Manuscript Download (1MB)
	Text AWZ1066S, a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis.pdf - Published version Download (1MB)

Abstract

Onchocerciasis and lymphatic filariasis are two neglected tropical diseases that together affect ∼157 million people and inflict severe disability. Both diseases are caused by parasitic filarial nematodes with elimination efforts constrained by the lack of a safe drug that can kill the adult filaria (macrofilaricide). Previous proof-of-concept human trials have demonstrated that depleting >90% of the essential nematode endosymbiont bacterium, Wolbachia, using antibiotics, can lead to permanent sterilization of adult female parasites and a safe macrofilaricidal outcome. AWZ1066S is a highly specific anti-Wolbachia candidate selected through a lead optimization program focused on balancing efficacy, safety and drug metabolism/pharmacokinetic (DMPK) features of a thienopyrimidine/quinazoline scaffold derived from phenotypic screening. AWZ1066S shows superior efficacy to existing anti-Wolbachia therapies in validated preclinical models of infection and has DMPK characteristics that are compatible with a short therapeutic regimen of 7 days or less. This candidate molecule is well-positioned for onward development and has the potential to make a significant impact on communities affected by filariasis.

Item Type:	Article
Uncontrolled Keywords:	onchocerciasis, lymphatic filariasis, anti-Wolbachia, drug discovery, macrofilaricide
Depositing User:	Symplectic Admin
Date Deposited:	24 Apr 2019 13:41
Last Modified:	19 Jan 2023 00:53
DOI:	10.1073/pnas.1816585116
Related Websites:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3038180
Disclaimer:	The University of Liverpool is not responsible for content contained on other websites from links within repository metadata. Please contact us if you notice anything that appears incorrect or inappropriate.

Available Versions of this Item

• AWZ1066S, a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis (deposited 17 Jan 2019 11:40)
  • AWZ1066S, a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis (deposited 24 Apr 2019 13:41) [Currently Displayed]